** Sun Pharmaceutical SUN.NS gains 4.4% in holiday-curtailed week; set for best weekly performance since late September 2024
** Drugmaker top weekly gainer on Nifty 50 .NSEI and pharma .NIPHARM indexes
** SUN gained in all sessions this week after $355 million deal for Checkpoint Therapeutics CKPT.O
** Analysts backed the deal, saying it would complement SUN's specialty portfolio
** Stock rated "buy" on avg, per data compiled by LSEG
** YTD, SUN down 11% vs NSEI's 4.7% drop
(Reporting by Nandan Mandayam in Bengaluru)
((Nandan.Mandayam@thomsonreuters.com; Mobile: +91 9591011727;))
免责声明:投资有风险,本文并非投资建议,以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请,作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考,不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证,投资者应自行研究并在投资前寻求专业建议。